BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:31 PM
 | 
Jun 01, 2009
 |  BC Extra  |  Clinical News

ChemoCentryx reports Crohn's data

ChemoCentryx Inc. (Mountain View, Calif.) said 500 mg once-daily oral Traficet-EN met the primary endpoint in the first part of the Phase II/III PROTECT-1 trial to treat Crohn's disease....

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >